Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cullgen (Shanghai) Inc. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 2 pending office actions, which are being handled by 2 distinct examiners. This distribution indicates that each pending matter is under the review of a different individual, providing two separate perspectives on the company's technology. The presence of 2 distinct art units suggests that the company's intellectual property is divided between two separate technical classifications at the patent office.
The busiest examiner for this portfolio is HIRAKIS, SOPHIA P, who is responsible for 1 pending office action. Since the total number of pending office actions is 2, the workload is evenly split between the 2 distinct examiners. This means that no single examiner dominates the current prosecution landscape for the company. Practitioners should note that they will need to manage two different examiner relationships and sets of procedural preferences simultaneously, as the 1 pending action per examiner creates a balanced workload.
The alignment of 2 distinct examiners across 2 distinct art units suggests that each examiner is operating within a unique technical environment. This lack of overlap between the art units and examiners means that the prosecution of one matter may not provide direct insights into the other. The workload of 1 pending action for the busiest examiner reflects this balanced distribution. A practitioner must ensure that the legal strategy remains consistent across the 2 pending office actions despite the different art units and examiners involved in the process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIRAKIS, SOPHIA P | 1 | 57.4% | +69.8% |
| WILSON, JERICA KATLYNN | 1 | 60.5% | +39.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043269 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | WILSON, JERICA KATLYNN | 59d overdue |
| 18700898 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | HIRAKIS, SOPHIA P | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18700898 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | HIRAKIS, SOPHIA P | 1623 | §112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18043269 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | WILSON, JERICA KATLYNN | 1621 | DP | Final Rejection | 59d overdue | Pending | Feb 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCullgen (Shanghai) Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sophia P Hirakis has the most, with 1 of Cullgen (Shanghai) Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
